Only 29 % of the populace acknowledged and recognized themselves as having accurate risk for a future heart attack. A small part of the survey participants – – 14 % – – said that they had no risk factors, and 4 % experienced suffered a previous heart attack. The survey also exposed some early indicators for heart disease within the mark group. They are: – – 55 % of ladies said these were at least 20 pounds obese – – 44 % of women said they possess a family history of heart attacks – – 32 % of females reported high blood pressure and/or high cholesterol – – 13 % of females smoke – – ten % of females have diabetes ‘Our biggest challenge in preventing heart disease and heart episodes is certainly changing behaviors,’ explains Meg Durbin, M.D., a grouped family members practice physician with Palo Alto Medical Basis.The positive basic safety profile to date suggests the drug may be tolerated at higher levels than 400 mg weekly and so the Company is considering the prospect of conducting a small add-on study to aid the use of an increased dose in Stage III trials for dose escalation in patients with an increase of active disease. Enrolment into the 24 patient trial is expected to be completed early in the brand new year. THE BUSINESS looks forwards to the reporting of the statistical analysis of the sIGF-I data from all individuals and to the potential verification of outcomes achieved in this interim analysis. Other important parameters of drug activity becoming measured in every patients which will also be assessed by the end of the study include Growth Hormone and GROWTH HORMONES Binding Protein levels along with a more comprehensive assessment of the security data.